Richard W. Martin, Ph.D., is a registered patent attorney focusing on prosecution, counseling, and litigation in the life sciences sector. Rich represents universities, emerging biotechnology companies, and large pharmaceutical clients before the US Patent and Trademark Office (USPTO) and US District Courts. His practice encompasses diverse technical subject matter, including biologic and small molecule pharmaceuticals, stem cells, transgenic animal and plant technology, genomics, metabolomics, microbiomics, and diagnostic methods.
Rich has prepared and prosecuted patents in the USPTO, internationally under the Patent Cooperation Treaty, and coordinated foreign prosecution in various jurisdictions. He has represented clients in post-grant proceedings before the Patent Trial and Appeal Board, including interference and inter partes review proceedings. His District Court experience includes ANDA litigation under the Hatch-Waxman Act. Rich has also counseled biosimilar applicants contemplating market approval under the Biologics Price Competition and Innovation Act.
Rich received his Ph.D. from the University of Chicago in the department of molecular genetics and cell biology. His doctoral work focused on the role of the breast cancer susceptibility gene BRCA1 in maintaining genome integrity, particularly its involvement in DNA signaling and repair pathways.
Before joining Morgan Lewis, Rich was an associate at a Chicago-based Intellectual Property boutique where he focused on life sciences patent matters. Prior to and during law school he served as a technical advisor with two prominent patent litigation practices.
Chicago-Kent College of Law, 2012, J.D.
University of Chicago, 2007, Ph.D., Molecular Genetics and Cell Biology